Literature DB >> 17221321

Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

J Helen Yoo1, Maria G Valdovinos, Dean C Williams.   

Abstract

This review discusses the laboratory and clinical research supporting the rationale for the efficacy of donepezil (Aricept USA) in enhancing cognition in autism, Alzheimer disease, Down syndrome, traumatic brain injury, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia. While preliminary animal models have shown effective, human studies exclusive of Alzheimer disease are sparse. Although attention and memory are unlikely a sole operation of the cholinergic system, evidence indicates a promising direction for further examination of this hypothesis in autism. Studies that examine changes in operationally defined behaviors and reliable and valid measure of changes in attention and memory are needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17221321     DOI: 10.1007/s10803-006-0322-8

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  111 in total

1.  Brain injury, cognitive impairment, and donepezil.

Authors:  J A Whitlock
Journal:  J Head Trauma Rehabil       Date:  1999-08       Impact factor: 2.710

2.  Cholinergic therapy for Down's syndrome.

Authors:  P S Kishnani; J A Sullivan; B K Walter; G A Spiridigliozzi; P M Doraiswamy; K R Krishnan
Journal:  Lancet       Date:  1999-03-27       Impact factor: 79.321

3.  Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release.

Authors:  Lifen Zhang; Fu-Ming Zhou; John A Dani
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

4.  An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.

Authors:  Robert W Buchanan; Ann Summerfelt; Cenk Tek; James Gold
Journal:  Schizophr Res       Date:  2003-01-01       Impact factor: 4.939

5.  Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Hongxin Dong; Cynthia A Csernansky; Maureen V Martin; Amy Bertchume; Dana Vallera; John G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 6.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

7.  Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.

Authors:  S L Rogers; L T Friedhoff
Journal:  Eur Neuropsychopharmacol       Date:  1998-02       Impact factor: 4.600

Review 8.  Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders.

Authors:  A J Graham; C M Martin-Ruiz; T Teaktong; M A Ray; J A Court
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-08

9.  Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study.

Authors:  Ziad Nahas; Mark S George; Michael D Horner; John S Markowitz; Xingbao Li; Jeffrey P Lorberbaum; Susan D Owens; Susan McGurk; Lindsay DeVane; S Craig Risch
Journal:  Neurocase       Date:  2003-06       Impact factor: 0.881

10.  A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.

Authors:  Onder Tuğal; Kâzm M Yazici; A Elif Anil Yağcioğlu; Ahmet Göğüş
Journal:  Int J Neuropsychopharmacol       Date:  2004-01-23       Impact factor: 5.176

View more
  11 in total

1.  Gonadal hormones modulate the potency of the disruptive effects of donepezil in male rats responding under a nonspatial operant learning and performance task.

Authors:  Stuart T Leonard; John K Hearn; Andrew D Catling; Peter J Winsauer
Journal:  Behav Pharmacol       Date:  2010-03       Impact factor: 2.293

2.  An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders.

Authors:  Ashura Williams Buckley; Kenneth Sassower; Alcibiades J Rodriguez; Kaitlin Jennison; Katherine Wingert; Jack Buckley; Audrey Thurm; Susumu Sato; Susan Swedo
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-08       Impact factor: 2.576

3.  Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures.

Authors:  Benjamin L Handen; Cynthia R Johnson; Sarah McAuliffe-Bellin; Patricia Jo Murray; Antonio Y Hardan
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-02       Impact factor: 2.576

Review 4.  Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders.

Authors:  Michael J Murray
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

5.  Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism.

Authors:  Golan Karvat; Tali Kimchi
Journal:  Neuropsychopharmacology       Date:  2013-10-07       Impact factor: 7.853

6.  Different cholinergic cell groups in the basal forebrain regulate social interaction and social recognition memory.

Authors:  Kana Okada; Kayo Nishizawa; Tomoko Kobayashi; Shogo Sakata; Kouichi Hashimoto; Kazuto Kobayashi
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

7.  The intense world theory - a unifying theory of the neurobiology of autism.

Authors:  Kamila Markram; Henry Markram
Journal:  Front Hum Neurosci       Date:  2010-12-21       Impact factor: 3.169

Review 8.  On the diagnostic and neurobiological origins of bipolar disorder.

Authors:  Alexander W Charney; Niamh Mullins; You Jeong Park; Jonathan Xu
Journal:  Transl Psychiatry       Date:  2020-04-23       Impact factor: 6.222

9.  Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence.

Authors:  Ramit Sharma; Saloni Rahi; Sidharth Mehan
Journal:  Toxicol Rep       Date:  2019-11-05

Review 10.  Donepezil for dementia in people with Down syndrome.

Authors:  Monica Mohan; Peter K Carpenter; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.